NCT02141230View on ClinicalTrials.gov

Risk Management Plan (RMP) Survey for Purchasers of Alli® (60 mg Orlistat) in the European Union.

NAWithdrawnINTERVENTIONAL

0

Timeline

Start Date

December 31, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions

Weight Loss

Interventions

DRUG

Alli® 60 mg

Participants purchasing Alli®

Sponsors

Lead Sponsor

GlaxoSmithKline

Collaborators (1)

All Listed Sponsors

collaborator

Hamell

UNKNOWN

lead

GlaxoSmithKline

INDUSTRY

NCT02141230 - Risk Management Plan (RMP) Survey for Purchasers of Alli® (60 mg Orlistat) in the European Union. | Biotech Hunter | Biotech Hunter